Pierre Fabre Pharmaceuticals Submits Type A Meeting Request to U.S. Food and Drug Administration (FDA) for Tabelecleucel Biologic License Application (BLA)

BLA FilingtabelecleucelPositive

AI Analysis

Summary

Pierre Fabre Pharmaceuticals submitted a Type A meeting request to the FDA regarding the biologic license application for tabelecleucel, an allogeneic T-cell therapy. The meeting request represents a regulatory step in the BLA process.

Outcome Details

Type A meeting request submitted to FDA for biologic license application

Importance:6/10

Sentiment:

0.50

FDABLAbiologicallogeneic T-cell therapyType A meeting

Read the original article

Published by PR Newswire Biotech on March 3, 2026 12:59 PM

Read Original